Oncology Dealmaking In The Wake Of Changing Regulatory And Reimbursement Decisions
This article was originally published in Start Up
Executive Summary
As big drugmakers move wholeheartedly into oncology, changing regulatory and reimbursement standards have dramatic implications for dealmaking - especially for smaller venture-backed start-ups who hope to sign lucrative alliances or M&A deals with deeper-pocketed partners.
You may also be interested in...
START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In
In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."
START-UP's 2011 Life Science Venture Capital Survey: Biopharmaceutical Investors Let Some Sunshine In
In START-UP's first life science venture survey, biopharma investors have plenty to complain about -- and they do -- but their generally positive outlook stands in contrast to that of their peers focused on medtech. Includes sidebar, "VCs Survive Amid Few Exits And Many Goodbyes."
What New Cancer Pathway Programs Mean For The Drug Industry
New efforts by US payors suggest oncologics no longer enjoy the same protected reimbursement status they once did, potentially pulling the rug from under biopharma's hottest development, dealmaking, and revenue generating activities. To succeed in an increasingly competitive marketplace, biopharmas must adapt their strategies with an eye to reducing payors' overall costs.